- Created on the 20 March, 2017.
Interferon-beta (IFN-beta) is a cytokine that is produced in large quantities by fibroblasts and many pathogens (exposed macrophages, endothelial and dendritic cells). Currently, there are at least two different types that have been identified IFN-β1 (IFNB1) and IFN-β3 (IFNB3). Also, a gene that has been designed IFN-β2 is in fact IL-6. IFN-β is found to be secreted by many cell types such as macrophages, endothelial cells, fibroblasts, osteoblasts and lymphocytes (this can include B-cells, T-cells and NK cells). IFN-beta has the ability to stimulate both NK and macrophage cells in order to elicit an anti-viral response, whilst they can also be active against tumors. It mainly signal using the heterodimeric IFN-alpha/beta receptor.
Another function of Interferon beta is to balance the expression of pro- and anti-inflammatory agents within the brain and thereby reduce the number of inflammatory cells that are able to cross the blood brain barrier. Generally therapy using IFN-β can lead to a reduction of neuron inflammation, it is also thought to increase the production of nerve growth factor and improve survival of neurons. In vitro studies show that interferon beta has the ability to reduce the production of Th17 cells (a subset of T lymphocytes) that are strongly believed to have an important role in the pathophysiology of multiple sclerosis. Interferons can reduce relapses by approx. 30% and their safe profile makes them ideal as the first-line treatment.
Human IFN-beta ELISA kit is intended for measuring in vitro quantitative amounts of interferon-beta (IFN-beta, IFN-β) in human plasma, serum, cell lysates, cell culture supernatant, tissue homogenates and other biological fluids. This assay has a minimum detection limit of < 2.8 pg/ml.
The minimum detection sensitivity level of interferon-beta (IFN-beta or IFN-β) using this human IFN-beta ELISA kit was 2.8 ng/ml. The dynamic assay range for this kit is 7.8 – 500 pg/ml.
- The conundrum of interferon-β non-responsiveness in relapsing-remitting multiple sclerosis. Cytokine. (2015) 74 (2): 228-36. Huber A.K., et al.
- Biomarkers of interferon Beta therapy in multiple sclerosis. J Interferon Cytokine Res. (2014) 34 (8): 600-4. Review. Graber J.J. and Dhib-Jalbut S.
- Interferon-beta responders and non-responders. A biological approach. Neurol Sci. (2008) 29 Suppl 2: S216-7. Review. Bertolotto A. and Gilli F.
- Interferon-Beta, a Decisive Factor in Angiogenesis and Arteriogenesis. J Interferon Cytokine Res. (2015) 35 (6): 411-20. Review. Yıldırım C., et al.
- Interferon-β exacerbates Th17-mediated inflammatory disease. Trends Immunol. (2011) 32 (6): 272-7. Review. Axtell R.C., et al.
- Full Name: Interferon-Beta (IFN-Beta) ELISA Kit
- Reactivity: Human
- Sample Type: Serum, Plasma, Tissue Homogenate, Cell Culture Supernatant, Cell Lysates, Other Biological Fluids
- Sensitivity: < 2.8 pg/ml